CERS · Insider Trading
Cerus Corp
Every open-market purchase and sale reported by CERS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Chrystal Jensen | Chief Legal Officer | Sell | −30,000 | −$89.53K |
| 2026-07-20 | Vivek K Jayaraman | Chief Executive Officer | Sell | −16,666 | −$52.66K |
| 2026-07-02 | Chrystal Jensen | Chief Legal Officer | MIXED | −79,329 | −$71.60K |
| 2026-07-02 | Vivek K Jayaraman | Chief Operating Officer | MIXED | +432,170 | −$124.66K |
| 2026-07-02 | William Mariner Greenman | President and CEO | MIXED | −294,419 | −$299.94K |
| 2026-07-02 | Kevin Dennis Green | Chief Financial Officer | MIXED | −97,276 | −$99.11K |
| 2026-06-11 | Eric Bjerkholt | Director | Sell | −20,454 | −$53.18K |
| 2026-06-02 | Eric Bjerkholt | Director | A | +60,000 | — |
| 2026-06-02 | Frank Witney | Director | A | +60,000 | — |
| 2026-06-02 | Ann Lucena | Director | A | +60,000 | — |
| 2026-06-02 | Dean A. Gregory | Director | A | +60,000 | — |
| 2026-06-02 | Hua Shan | Director | A | +60,000 | — |
| 2026-06-02 | Jami K Nachtsheim | Director | A | +60,000 | — |
| 2026-06-02 | Vivek K Jayaraman | Chief Operating Officer | Sell | −16,667 | −$50.00K |
| 2026-05-05 | Vivek K Jayaraman | Chief Operating Officer | Sell | −16,667 | −$50.00K |
| 2026-04-03 | Kevin Dennis Green | Chief Financial Officer | A | +200,000 | — |
| 2026-04-03 | Chrystal Jensen | Chief Legal Officer | A | +200,000 | — |
| 2026-03-16 | Richard J Benjamin | Chief Medical Officer | Sell | −101,740 | −$168.60K |
| 2026-03-16 | William Mariner Greenman | President and CEO | Sell | −447,757 | −$742.02K |
| 2026-03-16 | Kevin Dennis Green | Chief Financial Officer | Sell | −127,544 | −$211.37K |
| 2026-03-16 | Vivek K Jayaraman | Chief Operating Officer | Sell | −165,200 | −$273.77K |
| 2026-03-16 | Chrystal Jensen | Chief Legal Officer | Sell | −113,008 | −$187.28K |
| 2026-03-10 | Richard J Benjamin | Chief Medical Officer | MIXED | −70,674 | −$250.93K |
| 2026-03-09 | Vivek K Jayaraman | Chief Operating Officer | MIXED | +46,226 | −$68.38K |
| 2026-03-09 | Kevin Dennis Green | Chief Financial Officer | MIXED | −19,167 | −$169.65K |
| 2026-03-09 | William Mariner Greenman | President and CEO | MIXED | +115,083 | −$156.80K |
| 2026-03-09 | Chrystal Jensen | Chief Legal Officer | MIXED | +24,375 | −$61.86K |
| 2026-03-09 | Richard J Benjamin | Chief Medical Officer | MIXED | −70,674 | −$250.94K |
| 2026-03-04 | Vivek K Jayaraman | Chief Operating Officer | A | +420,000 | — |
| 2026-03-04 | Kevin Dennis Green | Chief Financial Officer | A | +300,000 | — |
| 2026-03-04 | Richard J Benjamin | Chief Medical Officer | A | +264,000 | — |
| 2026-03-04 | Chrystal Jensen | Chief Legal Officer | A | +300,000 | — |
| 2026-03-04 | William Mariner Greenman | President and CEO | A | +1,200,000 | — |
| 2025-11-26 | Chrystal Jensen | Chief Legal Officer | Sell | −55,000 | −$93.50K |
| 2025-08-25 | Dean A. Gregory | Director | Buy | +25,000 | +$31.25K |
| 2025-06-04 | Hua Shan | Director | A | +60,000 | — |
| 2025-06-04 | Daniel N Swisher JR | Director | A | +60,000 | — |
| 2025-06-04 | Timothy L. Moore | Director | A | +60,000 | — |
| 2025-06-04 | Jami K Nachtsheim | Director | A | +60,000 | — |
| 2025-06-04 | Eric Bjerkholt | Director | A | +60,000 | — |
| 2025-06-04 | Ann Lucena | Director | A | +60,000 | — |
| 2025-06-04 | Frank Witney | Director | A | +60,000 | — |
| 2025-03-17 | Richard J Benjamin | Chief Medical Officer | Sell | −49,024 | −$71.08K |
| 2025-03-17 | Chrystal Jensen | Chief Legal Officer | Sell | −49,024 | −$71.08K |
| 2025-03-17 | Vivek K Jayaraman | Chief Operating Officer | Sell | −75,989 | −$110.18K |
| 2025-03-17 | William Mariner Greenman | President and CEO | Sell | −193,913 | −$281.17K |
| 2025-03-17 | Kevin Dennis Green | Chief Financial Officer | Sell | −59,887 | −$86.84K |
| 2025-03-10 | Chrystal Jensen | Chief Legal Officer | MIXED | +427,120 | −$41.13K |
| 2025-03-10 | Vivek K Jayaraman | Chief Operating Officer | MIXED | +601,487 | −$50.93K |
| 2025-03-10 | Richard J Benjamin | Chief Medical Officer | MIXED | +340,426 | −$39.16K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William Mariner Greenman | President and CEO | 5,154,955 | $12.22M |
| Vivek K Jayaraman | Chief Executive Officer | 2,232,211 | $5.29M |
| Kevin Dennis Green | Chief Financial Officer | 1,095,864 | $2.60M |
| Chrystal Jensen | Chief Legal Officer | 936,657 | $2.22M |
| Richard J Benjamin | Chief Medical Officer | 777,361 | $1.84M |
| Frank Witney | Director | 340,059 | $805.94K |
| Jami K Nachtsheim | Director | 268,362 | $636.02K |
| Eric Bjerkholt | Director | 261,679 | $620.18K |
| Ann Lucena | Director | 232,284 | $550.51K |
| Daniel N Swisher JR | Director | 207,045 | $490.70K |
| Timothy L. Moore | Director | 205,073 | $486.02K |
| Hua Shan | Director | 192,386 | $455.95K |
| Dean A. Gregory | Director | 146,725 | $347.74K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CERS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.